CASI Pharmaceuticals Inc., based in Rockville, Maryland, is a biopharmaceutical firm focused on developing and commercializing innovative therapies for cancer and other serious diseases. The company is well-positioned to exploit both the expansive Chinese market and global healthcare prospects, utilizing its strong research and development capabilities to target significant unmet medical needs. With a diverse pipeline of targeted therapies, CASI aims to meet the growing demand for novel treatment options, making it an attractive opportunity for institutional investors seeking exposure in the evolving biopharmaceutical landscape. Show more

Location: 1701-1702, CHINA CENTRAL OFFICE TOWER 1, BEIJING, CHINA, 100025, Beijing, 100025, China | Website: https://www.casipharmaceuticals.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

20.96M

52 Wk Range

$0.75 - $3.09

Previous Close

$0.99

Open

$0.99

Volume

52,007

Day Range

$0.99 - $1.03

Enterprise Value

34.51M

Cash

4.685M

Avg Qtr Burn

N/A

Insider Ownership

38.60%

Institutional Own.

39.20%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
EVOMELA (melphalan) Details Multiple myeloma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Inaticabtagene Autoleucel (CNCT-19) (Anti-CD19) Details Non-Hodgkin lymphoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BI-1206 (Anti-FcyRIIB antibody) + rituximab Details Blood cancer, Non-Hodgkin lymphoma, Solid tumor/s, Cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CID-103 Details Renal Allograft Antibody-Mediated Rejection (AMR)	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CID-103 Details Immune Thrombocytopenia (ITP)	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CB-5339 Details Multiple myeloma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.